Selected research
Market Structure
Global Monoclonal Antibody Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Monoclonal Antibody Medicine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Monoclonal Antibody Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Monoclonal Antibody Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Monoclonal Antibody Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Monoclonal Antibody Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Monoclonal Antibody Medicine include Sanofi, Johnson & Johnson, Novartis, Merck, Roche, Eli Lilly, Pfizer, Biogen and Amgen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Monoclonal Antibody Medicine market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Monoclonal Antibody Medicine and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Monoclonal Antibody Medicine revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Monoclonal Antibody Medicine market size, projected growth trends, production technologies, key applications, and end-use industries.
Monoclonal Antibody Medicine Segment by Company
Sanofi
Johnson & Johnson
Novartis
Merck
Roche
Eli Lilly
Pfizer
Biogen
Amgen
AbbVie
Sobi
Innovent Biologics
Celltrion
3SBIO
Monoclonal Antibody Medicine Segment by Type
Biologics
Biosimilars
Monoclonal Antibody Medicine Segment by Application
Cancer
Autoimmune Disease
Other
Monoclonal Antibody Medicine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Monoclonal Antibody Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Monoclonal Antibody Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Monoclonal Antibody Medicine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Monoclonal Antibody Medicine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Monoclonal Antibody Medicine industry.
Chapter 3: Detailed analysis of Monoclonal Antibody Medicine companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Monoclonal Antibody Medicinerevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Biologics
- Biosimilars
Applications
- Cancer
- Autoimmune Disease
- Other
Companies covered
- Sanofi
- Johnson & Johnson
- Novartis
- Merck
- Roche
- Eli Lilly
- Pfizer
- Biogen
- Amgen
- AbbVie
- Sobi
- Innovent Biologics
- Celltrion
- 3SBIO
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Monoclonal Antibody Medicine Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Biologics
- 1.2.3 Biosimilars
- 1.3 Market Analysis by Application
- 1.3.1 Global Monoclonal Antibody Medicine Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Cancer
- 1.3.3 Autoimmune Disease
- 1.3.4 Other
- 1.4 Global Market Growth Prospects
- 1.5 Global Monoclonal Antibody Medicine Growth Trends by Region
- 1.5.1 Global Monoclonal Antibody Medicine Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Monoclonal Antibody Medicine Market Size by Region (2021-2026)
- 1.5.3 Monoclonal Antibody Medicine Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Monoclonal Antibody Medicine Market Dynamics
- 2.1 Monoclonal Antibody Medicine Industry Trends
- 2.2 Monoclonal Antibody Medicine Industry Drivers
- 2.3 Monoclonal Antibody Medicine Industry Opportunities and Challenges
- 2.4 Monoclonal Antibody Medicine Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Monoclonal Antibody Medicine Revenue by Company (2021-2026)
- 3.2 Global Monoclonal Antibody Medicine Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Monoclonal Antibody Medicine Key Company Head office and Area Served
- 3.4 Global Monoclonal Antibody Medicine Company, Product Type & Application
- 3.5 Global Monoclonal Antibody Medicine Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Monoclonal Antibody Medicine Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Monoclonal Antibody Medicine Players Market Share by Revenue in 2025
- 3.6.3 2025 Monoclonal Antibody Medicine Tier 1, Tier 2, and Tier 3
4 Monoclonal Antibody Medicine Market by Type
- 4.1 Global Monoclonal Antibody Medicine Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Monoclonal Antibody Medicine Market Size by Type (2021-2032)
- 4.3 Global Monoclonal Antibody Medicine Market Size Share by Type (2021-2032)
5 Monoclonal Antibody Medicine Market by Application
- 5.1 Global Monoclonal Antibody Medicine Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Monoclonal Antibody Medicine Market Size by Application (2021-2032)
- 5.3 Global Monoclonal Antibody Medicine Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Sanofi
- 6.1.1 Sanofi Company Information
- 6.1.2 Sanofi Business Overview
- 6.1.3 Sanofi Monoclonal Antibody Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Sanofi Monoclonal Antibody Medicine Product Portfolio
- 6.1.5 Sanofi Recent Developments
- 6.2 Johnson & Johnson
- 6.2.1 Johnson & Johnson Company Information
- 6.2.2 Johnson & Johnson Business Overview
- 6.2.3 Johnson & Johnson Monoclonal Antibody Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Johnson & Johnson Monoclonal Antibody Medicine Product Portfolio
- 6.2.5 Johnson & Johnson Recent Developments
- 6.3 Novartis
- 6.3.1 Novartis Company Information
- 6.3.2 Novartis Business Overview
- 6.3.3 Novartis Monoclonal Antibody Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Novartis Monoclonal Antibody Medicine Product Portfolio
- 6.3.5 Novartis Recent Developments
- 6.4 Merck
- 6.4.1 Merck Company Information
- 6.4.2 Merck Business Overview
- 6.4.3 Merck Monoclonal Antibody Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Merck Monoclonal Antibody Medicine Product Portfolio
- 6.4.5 Merck Recent Developments
- 6.5 Roche
- 6.5.1 Roche Company Information
- 6.5.2 Roche Business Overview
- 6.5.3 Roche Monoclonal Antibody Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Roche Monoclonal Antibody Medicine Product Portfolio
- 6.5.5 Roche Recent Developments
- 6.6 Eli Lilly
- 6.6.1 Eli Lilly Company Information
- 6.6.2 Eli Lilly Business Overview
- 6.6.3 Eli Lilly Monoclonal Antibody Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Eli Lilly Monoclonal Antibody Medicine Product Portfolio
- 6.6.5 Eli Lilly Recent Developments
- 6.7 Pfizer
- 6.7.1 Pfizer Company Information
- 6.7.2 Pfizer Business Overview
- 6.7.3 Pfizer Monoclonal Antibody Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Pfizer Monoclonal Antibody Medicine Product Portfolio
- 6.7.5 Pfizer Recent Developments
- 6.8 Biogen
- 6.8.1 Biogen Company Information
- 6.8.2 Biogen Business Overview
- 6.8.3 Biogen Monoclonal Antibody Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Biogen Monoclonal Antibody Medicine Product Portfolio
- 6.8.5 Biogen Recent Developments
- 6.9 Amgen
- 6.9.1 Amgen Company Information
- 6.9.2 Amgen Business Overview
- 6.9.3 Amgen Monoclonal Antibody Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Amgen Monoclonal Antibody Medicine Product Portfolio
- 6.9.5 Amgen Recent Developments
- 6.10 AbbVie
- 6.10.1 AbbVie Company Information
- 6.10.2 AbbVie Business Overview
- 6.10.3 AbbVie Monoclonal Antibody Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 AbbVie Monoclonal Antibody Medicine Product Portfolio
- 6.10.5 AbbVie Recent Developments
- 6.11 Sobi
- 6.11.1 Sobi Company Information
- 6.11.2 Sobi Business Overview
- 6.11.3 Sobi Monoclonal Antibody Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Sobi Monoclonal Antibody Medicine Product Portfolio
- 6.11.5 Sobi Recent Developments
- 6.12 Innovent Biologics
- 6.12.1 Innovent Biologics Company Information
- 6.12.2 Innovent Biologics Business Overview
- 6.12.3 Innovent Biologics Monoclonal Antibody Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Innovent Biologics Monoclonal Antibody Medicine Product Portfolio
- 6.12.5 Innovent Biologics Recent Developments
- 6.13 Celltrion
- 6.13.1 Celltrion Company Information
- 6.13.2 Celltrion Business Overview
- 6.13.3 Celltrion Monoclonal Antibody Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Celltrion Monoclonal Antibody Medicine Product Portfolio
- 6.13.5 Celltrion Recent Developments
- 6.14 3SBIO
- 6.14.1 3SBIO Company Information
- 6.14.2 3SBIO Business Overview
- 6.14.3 3SBIO Monoclonal Antibody Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 3SBIO Monoclonal Antibody Medicine Product Portfolio
- 6.14.5 3SBIO Recent Developments
7 North America
- 7.1 North America Monoclonal Antibody Medicine Market Size (2021-2032)
- 7.2 North America Monoclonal Antibody Medicine Market Size by Type
- 7.2.1 North America Monoclonal Antibody Medicine Market Size by Type (2021-2026)
- 7.2.2 North America Monoclonal Antibody Medicine Market Size by Type (2027-2032)
- 7.2.3 North America Monoclonal Antibody Medicine Market Share by Type (2021-2032)
- 7.3 North America Monoclonal Antibody Medicine Market Size by Application
- 7.3.1 North America Monoclonal Antibody Medicine Market Size by Application (2021-2026)
- 7.3.2 North America Monoclonal Antibody Medicine Market Size by Application (2027-2032)
- 7.3.3 North America Monoclonal Antibody Medicine Market Share by Application (2021-2032)
- 7.4 North America Monoclonal Antibody Medicine Market Size by Country
- 7.4.1 North America Monoclonal Antibody Medicine Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Monoclonal Antibody Medicine Market Size by Country (2021-2026)
- 7.4.3 North America Monoclonal Antibody Medicine Market Size by Country (2027-2032)
- 7.4.4 North America Monoclonal Antibody Medicine Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Monoclonal Antibody Medicine Market Size (2021-2032)
- 8.2 Europe Monoclonal Antibody Medicine Market Size by Type
- 8.2.1 Europe Monoclonal Antibody Medicine Market Size by Type (2021-2026)
- 8.2.2 Europe Monoclonal Antibody Medicine Market Size by Type (2027-2032)
- 8.2.3 Europe Monoclonal Antibody Medicine Market Share by Type (2021-2032)
- 8.3 Europe Monoclonal Antibody Medicine Market Size by Application
- 8.3.1 Europe Monoclonal Antibody Medicine Market Size by Application (2021-2026)
- 8.3.2 Europe Monoclonal Antibody Medicine Market Size by Application (2027-2032)
- 8.3.3 Europe Monoclonal Antibody Medicine Market Share by Application (2021-2032)
- 8.4 Europe Monoclonal Antibody Medicine Market Size by Country
- 8.4.1 Europe Monoclonal Antibody Medicine Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Monoclonal Antibody Medicine Market Size by Country (2021-2026)
- 8.4.3 Europe Monoclonal Antibody Medicine Market Size by Country (2027-2032)
- 8.4.4 Europe Monoclonal Antibody Medicine Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Monoclonal Antibody Medicine Market Size (2021-2032)
- 9.2 China Monoclonal Antibody Medicine Market Size by Type
- 9.2.1 China Monoclonal Antibody Medicine Market Size by Type (2021-2026)
- 9.2.2 China Monoclonal Antibody Medicine Market Size by Type (2027-2032)
- 9.2.3 China Monoclonal Antibody Medicine Market Share by Type (2021-2032)
- 9.3 China Monoclonal Antibody Medicine Market Size by Application
- 9.3.1 China Monoclonal Antibody Medicine Market Size by Application (2021-2026)
- 9.3.2 China Monoclonal Antibody Medicine Market Size by Application (2027-2032)
- 9.3.3 China Monoclonal Antibody Medicine Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Monoclonal Antibody Medicine Market Size (2021-2032)
- 10.2 Asia Monoclonal Antibody Medicine Market Size by Type
- 10.2.1 Asia Monoclonal Antibody Medicine Market Size by Type (2021-2026)
- 10.2.2 Asia Monoclonal Antibody Medicine Market Size by Type (2027-2032)
- 10.2.3 Asia Monoclonal Antibody Medicine Market Share by Type (2021-2032)
- 10.3 Asia Monoclonal Antibody Medicine Market Size by Application
- 10.3.1 Asia Monoclonal Antibody Medicine Market Size by Application (2021-2026)
- 10.3.2 Asia Monoclonal Antibody Medicine Market Size by Application (2027-2032)
- 10.3.3 Asia Monoclonal Antibody Medicine Market Share by Application (2021-2032)
- 10.4 Asia Monoclonal Antibody Medicine Market Size by Country
- 10.4.1 Asia Monoclonal Antibody Medicine Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Monoclonal Antibody Medicine Market Size by Country (2021-2026)
- 10.4.3 Asia Monoclonal Antibody Medicine Market Size by Country (2027-2032)
- 10.4.4 Asia Monoclonal Antibody Medicine Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Monoclonal Antibody Medicine Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Monoclonal Antibody Medicine Market Size by Type
- 11.2.1 South America, Middle East & Africa Monoclonal Antibody Medicine Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Monoclonal Antibody Medicine Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Monoclonal Antibody Medicine Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Monoclonal Antibody Medicine Market Size by Application
- 11.3.1 South America, Middle East & Africa Monoclonal Antibody Medicine Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Monoclonal Antibody Medicine Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Monoclonal Antibody Medicine Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Monoclonal Antibody Medicine Market Size by Country
- 11.4.1 South America, Middle East & Africa Monoclonal Antibody Medicine Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Monoclonal Antibody Medicine Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Monoclonal Antibody Medicine Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Monoclonal Antibody Medicine Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst